Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
AU2018381874A1
Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
GB201815696D0
Synthetic method
GB201815695D0
Synthetic method
GB201815699D0
Synthetic method
GB201802354D0
Treatment of chronic obstructive pulmonary disease
GB201802353D0
Treatment of chronic obstructive pulmonary disease
GB201720624D0
Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations
GB201612238D0
Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0
Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
KR20180118667A
Dosage regimen for acute exacerbation of chronic obstructive pulmonary disease
KR20180119597A
Methods for the treatment of acute exacerbation of inflammatory conditions
GB201602249D0
Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
GB201602248D0
Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
NZ628392A
Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
